Immunotherapy of AML expressing mtNPM1 with anti-CD33 or CD123 strategies [55–57], anti-PD1 or PD-L1 antibodies-based combinations [58, 59], or anti-CD123 directed chimeric antigen receptor (CAR-T) cells are also being investigated [60]. The gene discussed is CD33; the disease is acute myeloid leukemia.